HEALTHSTORY 838· JUNE 24, 2026

WHO-Backed Clinical Trial to Test Remdesivir and MBP-134 Against Bundibugyo Ebolavirus in DRC

A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 837Asia Technology Stocks Mostly Rebound After Global Rout; Samsung Gains 9%NEXT STORY 839 →Federal Judge Blocks Texas Prosecutors From Subpoenaing Transgender Patient Records at New York Hospitals

Keep reading

More from the desk.

23HEALTH

Spruce Biosciences taps Adrian Quartel for chief medical officer role

A chief medical officer is the executive who decides how a drug company designs its clinical trials, interprets the data that comes back, and makes the medical case to regulators. Spruce Biosciences has filled that seat, hiring Adrian…

health1 MIN

34HEALTH

Federal health officials open a 30-day window to reconsider how children's vaccine recommendations are categorized

The federal government has taken a formal step toward reconsidering how children's vaccines are recommended in the United States, though no existing recommendations have changed. That step is a request for information

health2 MIN

48HEALTH

FDA clears Ultragenyx gene therapy in a week of back-to-back regulatory action

A gene therapy has received clearance for use in American patients, one of at least two approvals the Food and Drug Administration processed in a short stretch this week. Gene therapy, in p

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk